Physician profile
Zobair M Younossi
NPI 1194760298
$1,237,343.70
in general payments reported to CMS, 2019-2025
19 companies · $83K in 2025
The $83K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402K · 2020: $377K · 2021: $83K · 2022: $48K · 2023: $201K · 2024: $44K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $192K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $121K · Honoraria: $6,520 · Travel and Lodging: $4,999 · Food and Beverage: $2,264 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $192,200.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120,786.30 |
| Honoraria | $6,520.00 |
| Travel and Lodging | $4,999.16 |
| Food and Beverage | $2,264.24 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $665.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $610,090.57 | 2019-2025 | |
| Siemens Medical Solutions USA, INC. | $278,847.99 | 2019-2025 | Atellica Im 1300 Analyzer, Advia Chemistry Xpt System, Advia Centaur Xp Analyzer |
| Intercept Pharmaceuticals, INC. | $118,177.39 | 2019-2023 | Ocaliva |
| Novo Nordisk As | $112,540.23 | 2019-2022 | |
| Novo Nordisk INC | $38,234.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $14,590.08 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,702.16 | 2020-2024 | |
| Boehringer Ingelheim International Gmbh | $9,143.38 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $9,071.00 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $8,450.00 | 2020-2021 | |
| Madrigal Pharmaceuticals | $5,920.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $4,000.00 | 2019 | |
| Merck Sharp & Dohme LLC | $3,780.00 | 2021-2025 | |
| Ipsen Bioscience INC. | $3,320.00 | 2023 | |
| Bausch Health US, LLC | $2,407.03 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,404.33 | 2019-2025 | Xifaxan |
| Theratechnologies INC. | $2,000.00 | 2020 | |
| Mallinckrodt Hospital Products INC. | $2,000.00 | 2020 | |
| Dexcom, INC. | $665.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zobair Younossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.